adplus-dvertising
Connect with us

Business

Moderna may be superior to Pfizer against Delta; breakthrough odds rise with time – Yahoo News Canada

Published

 on


(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19. 

  Moderna’s vaccine may be best against Delta 

  The mRNA vaccine from Pfizer and BioNTech may be less effective than Moderna’s against the Delta variant of the coronavirus, according to two reports posted on medRxiv on Sunday ahead of peer review. In a study of more than 50,000 patients in the Mayo Clinic Health System https://bit.ly/37Btmhf, researchers found the effectiveness of Moderna’s vaccine against infection had dropped to 76% in July – when the Delta variant was predominant – from 86% in early 2021. Over the same period, the effectiveness of the Pfizer/BioNTech vaccine had fallen to 42% from 76%, researchers said. While both vaccines remain effective at preventing COVID hospitalization, a Moderna booster shot may be necessary soon for anyone who got the Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company nference, who led the Mayo study. 

  In a separate study, elderly nursing home residents in Ontario https://bit.ly/3sb9pHJ produced stronger immune responses – especially to worrisome variants – after the Moderna vaccine than after the Pfizer/BioNTech vaccine. The elderly may need higher vaccine doses, boosters, and other preventative measures, said Anne-Claude Gingras of the Lunenfeld-Tanenbaum Research Institute in Toronto, who led the Canadian study. When asked to comment on both research reports, a Pfizer spokesperson said, “We continue to believe… a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection.” 

  Breakthrough COVID-19 more likely months after vaccination 

  People who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago, new data suggest. Researchers studied nearly 34,000 fully vaccinated adults in Israel https://bit.ly/3Cucp6O who were tested to see if they had a breakthrough case of COVID-19. Overall, 1.8% tested positive. At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier, the research team reported Thursday on medRxiv ahead of peer review. Among patients older than 60, the odds of a positive test were almost three times higher when at least 146 days had passed since the second dose. Most of the new infections were observed recently, said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel. “Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,” he added. “We are planning to continue our research.” 

  Ovarian egg sacs not harmed by COVID-19 antibodies 

  The sacs in the ovaries where eggs are stored are not harmed by COVID-19 antibodies, whether those antibodies are the result of infection or vaccination, a small study https://bit.ly/3jFVCoQ suggests. Israeli researchers analyzed fluid from ovarian sacs, or follicles, from 32 women who were having their eggs retrieved to be fertilized by sperm in a test tube. Fourteen women had not been vaccinated against the coronavirus nor infected with it. The others had either recovered from COVID-19 or received the Pfizer/BioNTech mRNA vaccine, and in these two groups the researchers saw antibodies against the virus in follicle fluid. There was no difference among the groups in the follicles’ ability to make female sex hormones, nourish and nuture the egg so it will form a good quality embryo, and release the egg during ovulation. There was also no difference in “the rate of good quality embryos” from the eggs retrieved from each patient,” said Dr. Yaakov Bentov of Hadassah-Hebrew University Medical Center in Jerusalem, who coauthored a report published on Saturday in Human Reproduction. 

  Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development. 

  (Reporting by Nancy Lapid; Editing by Tiffany Wu) 

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Business

TC Energy cuts cost estimate for Southeast Gateway pipeline project in Mexico

Published

 on

 

CALGARY – TC Energy Corp. has lowered the estimated cost of its Southeast Gateway pipeline project in Mexico.

It says it now expects the project to cost between US$3.9 billion and US$4.1 billion compared with its original estimate of US$4.5 billion.

The change came as the company reported a third-quarter profit attributable to common shareholders of C$1.46 billion or $1.40 per share compared with a loss of C$197 million or 19 cents per share in the same quarter last year.

Revenue for the quarter ended Sept. 30 totalled C$4.08 billion, up from C$3.94 billion in the third quarter of 2023.

TC Energy says its comparable earnings for its latest quarter amounted to C$1.03 per share compared with C$1.00 per share a year earlier.

The average analyst estimate had been for a profit of 95 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:TRP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

BCE reports Q3 loss on asset impairment charge, cuts revenue guidance

Published

 on

 

BCE Inc. reported a loss in its latest quarter as it recorded $2.11 billion in asset impairment charges, mainly related to Bell Media’s TV and radio properties.

The company says its net loss attributable to common shareholders amounted to $1.24 billion or $1.36 per share for the quarter ended Sept. 30 compared with a profit of $640 million or 70 cents per share a year earlier.

On an adjusted basis, BCE says it earned 75 cents per share in its latest quarter compared with an adjusted profit of 81 cents per share in the same quarter last year.

“Bell’s results for the third quarter demonstrate that we are disciplined in our pursuit of profitable growth in an intensely competitive environment,” BCE chief executive Mirko Bibic said in a statement.

“Our focus this quarter, and throughout 2024, has been to attract higher-margin subscribers and reduce costs to help offset short-term revenue impacts from sustained competitive pricing pressures, slow economic growth and a media advertising market that is in transition.”

Operating revenue for the quarter totalled $5.97 billion, down from $6.08 billion in its third quarter of 2023.

BCE also said it now expects its revenue for 2024 to fall about 1.5 per cent compared with earlier guidance for an increase of zero to four per cent.

The company says the change comes as it faces lower-than-anticipated wireless product revenue and sustained pressure on wireless prices.

BCE added 33,111 net postpaid mobile phone subscribers, down 76.8 per cent from the same period last year, which was the company’s second-best performance on the metric since 2010.

It says the drop was driven by higher customer churn — a measure of subscribers who cancelled their service — amid greater competitive activity and promotional offer intensity. BCE’s monthly churn rate for the category was 1.28 per cent, up from 1.1 per cent during its previous third quarter.

The company also saw 11.6 per cent fewer gross subscriber activations “due to more targeted promotional offers and mobile device discounting compared to last year.”

Bell’s wireless mobile phone average revenue per user was $58.26, down 3.4 per cent from $60.28 in the third quarter of the prior year.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:BCE)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Canada Goose reports Q2 revenue down from year ago, trims full-year guidance

Published

 on

 

TORONTO – Canada Goose Holdings Inc. trimmed its financial guidance as it reported its second-quarter revenue fell compared with a year ago.

The luxury clothing company says revenue for the quarter ended Sept. 29 totalled $267.8 million, down from $281.1 million in the same quarter last year.

Net income attributable to shareholders amounted to $5.4 million or six cents per diluted share, up from $3.9 million or four cents per diluted share a year earlier.

On an adjusted basis, Canada Goose says it earned five cents per diluted share in its latest quarter compared with an adjusted profit of 16 cents per diluted share a year earlier.

In its outlook, Canada Goose says it now expects total revenue for its full financial year to show a low-single-digit percentage decrease to low-single-digit percentage increase compared with earlier guidance for a low-single-digit increase.

It also says it now expects its adjusted net income per diluted share to show a mid-single-digit percentage increase compared with earlier guidance for a percentage increase in the mid-teens.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:GOOS)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending